- Home
- RNG vs KNSA Comparison
RNG vs KNSA Comparison
Compare RNG & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNG | KNSA |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.5B |
| IPO Year | 2013 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RNG | KNSA |
|---|---|---|
| Price | $43.43 | $53.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 7 |
| Target Price | $33.58 | ★ $60.86 |
| AVG Volume (30 Days) | ★ 1.9M | 689.2K |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | ★ 0.75% | N/A |
| EPS Growth | 176.19 | ★ 225.00 |
| EPS | ★ 0.35 | 0.27 |
| Revenue | ★ $2,515,142,000.00 | $677,564,000.00 |
| Revenue This Year | $5.56 | $37.48 |
| Revenue Next Year | $4.56 | $17.87 |
| P/E Ratio | ★ $120.97 | $199.89 |
| Revenue Growth | 4.78 | ★ 60.09 |
| 52 Week Low | $23.59 | $26.27 |
| 52 Week High | $48.57 | $59.87 |
Technical Indicators
Market Signals| Indicator | RNG | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 55.25 | 50.44 |
| Support Level | $26.25 | $40.67 |
| Resistance Level | $43.83 | $59.87 |
| Average True Range (ATR) | 2.88 | 2.10 |
| MACD | -0.21 | -0.76 |
| Stochastic Oscillator | 51.14 | 13.23 |
Price Performance
Historical ComparisonAbout RNG RingCentral Inc.
RingCentral is a unified communications as a service, or UCaaS, provider. Its software helps users communicate and collaborate via voice, video, and messaging across all device types and all from one platform. RingCentral helps customers modernize and move from legacy on-premises systems to modern, cloud-based systems. Beyond its core RingCentral MVP solution, RingCentral also offers a cloud-based contact center solution, a stand-alone video meetings solution, and webinars.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.